MediciNova 경영진

경영진 기준 점검 2/4

MediciNova CEO는 Yuichi Iwaki, Jan2000 에 임명되었습니다 의 임기는 26.5 년입니다. 총 연간 보상은 $1.74M, 37.9% 급여 및 62.1% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $1.52M 가치에 해당하는 회사 주식의 2.22% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 10 년과 6.4 년입니다.

핵심 정보

Yuichi Iwaki

최고경영자

US$1.7m

총 보수

CEO 급여 비율	37.85%
CEO 재임 기간	26.5yrs
CEO 지분 보유율	2.2%
경영진 평균 재임 기간	10yrs
이사회 평균 재임 기간	6.4yrs

최근 경영진 업데이트

Recent updates

분석 기사 • Aug 28

Here's Why We're Not Too Worried About MediciNova's (NASDAQ:MNOV) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

분석 기사 • Oct 12

We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Seeking Alpha • Sep 15

MediciNova to get US patent for MN-166 to treat brain cancer

MediciNova (NASDAQ:MNOV) said it will receive a new patent from the U.S. Patent and Trademark Office which covers MN-166 (ibudilast) to treat glioblastoma. The new patent is expected to expire no earlier than February 2039, the company said in a Sept. 14 press release. Glioblastoma is a type of cancer that can occur in the brain or spinal cord. The allowed claims cover a method of treating a patient with glioblastoma or recurrent glioblastoma wherein a patient expresses unmethylated MGMT, using MN-166 (ibudilast) in combination with one or more other therapeutic agents. "Results of our glioblastoma animal model study showed that median survival was longer in the group that received combination treatment with MN-166 plus temozolomide compared to the group that received the standard treatment of temozolomide alone," said MediciNova Chief Medical Officer Kazuko Matsuda.

Seeking Alpha • Aug 16

MediciNova's MN-166 to be part of study to treat Long COVID

MediciNova (NASDAQ:MNOV) said it plans to participate in a grant-funded clinical trial, dubbed RECLAIM, to evaluate MN-166 (ibudilast) and other therapies for treating Long COVID. The company added that it reached an agreement to collaborate with the University Health Network.

Seeking Alpha • Jul 22

MediciNova begins study of parenteral formulation of MN-166

MediciNova (NASDAQ:MNOV) said it started a first-in-human study of a new parenteral formulation of MN-166 (ibudilast). The company said the newly developed MN-166 (ibudilast) formulation will provide an additional option besides the current oral formulation. "With MN-166 expected to be effective to treat a variety of diseases, we believe expanding to a parenteral formulation increases the feasibility of treating more target indications, thus increasing the value of MN-166," said MediciNova Chief Medical Officer Kazuko Matsuda. In April, the company reported data from a phase 2 trial of MN-166 for alcohol use disorder, showing that the drug reduced alcohol craving on non-drinking days.

Seeking Alpha • Jun 30

MediciNova announces extension of BARDA contract for Ibudilast development

MediciNova (NASDAQ:MNOV) said on Wednesday that a modification to its contract with the Biomedical Advanced Research and Development Authority (BARDA) for its small molecule candidate MN-166 (ibudilast). Under the partnership with BARDA, the company will repurpose MN-166 as a potential medical countermeasure against chlorine gas-induced lung damage such as acute respiratory distress syndrome (ARDS) and acute lung injury (ALI). The contract was amended to extend the period of performance until March 2023. BARDA, a division of the U.S. Department of Health and Human Services will fund the proof-of-concept studies in preclinical models of chlorine gas-induced acute lung injury. The project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority. Last year in March, MediciNova jumps on BARDA partnership for Ibudilast development. Shares are up 2.75% after-hours.

분석 기사 • Mar 19

We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

분석 기사 • Nov 23

MediciNova (NASDAQ:MNOV) Is In A Strong Position To Grow Its Business

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Seeking Alpha • Aug 31

MediciNova: The Pain Of A Positive Outlook

MediciNova reported blasé Q2 2021 earnings on 08/12/2021. MediciNova's core pipeline consists of two candidate therapies being developed in treatment of eleven indications. MediciNova's MS program is a high potential, late stage program which has been in stall mode. MediciNova has operated under less financial strain than expected for a company with its advanced pipeline.

Seeking Alpha • Jun 21

MediciNova stock climbs 31% on positive MN-166 data in mid-stage alcohol use disorder study

MediciNova (MNOV) soars 30.6% premarket after announcing positive results from a Phase 2 trial of MN-166 (ibudilast) in alcohol use disorder ((AUD)), published in Nature’s Translational Psychiatry. The Phase 2 trial evaluated the effect of 14 days of ibudilast treatment on mood, heavy drinking, and neural reward signals in individuals with AUD. A total of 52 patients were enrolled. Key results include: Ibudilast did not have a significant effect on negative mood.Ibudilast, relative to placebo, reduced the odds of heavy drinking across time

분석 기사 • May 15

Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

CEO 보수 분석

Yuichi Iwaki의 보수는 MediciNova의 수익에 비해 어떻게 변했나요?
날짜	총 보수	급여	회사 수익
Mar 31 2026	n/a	n/a	-US$12m
Dec 31 2025	US$2m	US$657k	-US$12m
Sep 30 2025	n/a	n/a	-US$12m
Jun 30 2025	n/a	n/a	-US$12m
Mar 31 2025	n/a	n/a	-US$11m
Dec 31 2024	US$1m	US$657k	-US$11m
Sep 30 2024	n/a	n/a	-US$10m
Jun 30 2024	n/a	n/a	-US$8m
Mar 31 2024	n/a	n/a	-US$8m
Dec 31 2023	US$1m	US$657k	-US$9m
Sep 30 2023	n/a	n/a	-US$10m
Jun 30 2023	n/a	n/a	-US$12m
Mar 31 2023	n/a	n/a	-US$14m
Dec 31 2022	US$1m	US$620k	-US$14m
Sep 30 2022	n/a	n/a	-US$13m
Jun 30 2022	n/a	n/a	-US$13m
Mar 31 2022	n/a	n/a	-US$13m
Dec 31 2021	US$3m	US$596k	-US$10m
Sep 30 2021	n/a	n/a	-US$11m
Jun 30 2021	n/a	n/a	-US$11m
Mar 31 2021	n/a	n/a	-US$11m
Dec 31 2020	US$3m	US$587k	-US$14m
Sep 30 2020	n/a	n/a	-US$13m
Jun 30 2020	n/a	n/a	-US$12m
Mar 31 2020	n/a	n/a	-US$11m
Dec 31 2019	US$4m	US$572k	-US$13m

보상 대 시장: Yuichi의 총 보수(USD1.74M)는 US 시장에서 비슷한 규모 기업의 평균(USD658.93K)보다 높습니다.

보상과 수익: Yuichi의 보상은 회사가 적자임에도 증가했습니다.

CEO

Yuichi Iwaki (76 yo)

26.5yrs

재임 기간

US$1,736,711

보수

Dr. Yuichi Iwaki, M.D., Ph D., is a Co-Founder of MediciNova Inc. and has been its Chief Executive Officer and President since March 2006 and as Chairman. Dr. Iwaki served as Acting Principal Financial Off...

리더십 팀

이름	직위	재임 기간	보수	지분
Yuichi Iwaki	Co-Founder	26.5yrs	US$1.74m	2.22% $ 1.5m
Kazuko Matsuda	Senior VP	14.8yrs	US$1.33m	0.66% $ 449.0k
David Crean	Chief Business Officer	5.2yrs	US$120.00k	0% $ 0
Jason Kruger	CFO & Principal Financial Officer	4.1yrs	데이터 없음	데이터 없음

10.0yrs

평균 재임 기간

60.5yo

평균 나이

경험이 풍부한 관리: MNOV의 경영진은 노련하고 경험이 풍부합니다(평균 재임 10 년).

이사회 구성원

이름	직위	재임 기간	보수	지분
Yuichi Iwaki	Co-Founder	25.8yrs	US$1.74m	2.22% $ 1.5m
Kazuko Matsuda	Senior VP	7yrs	US$1.33m	0.66% $ 449.0k
Hideki Nagao	Independent Director	8.7yrs	US$86.31k	0% $ 0
Carolyn Beaver	Independent Director	5.8yrs	US$86.31k	0% $ 0
Christopher Breder	Lead Scientific Advisory Board	less than a year	데이터 없음	데이터 없음
Nicole Lemerond	Independent Director	2.9yrs	US$86.31k	0% $ 0

6.4yrs

평균 재임 기간

68yo

평균 나이

경험이 풍부한 이사회: MNOV의 이사회는 경험이 있음으로 간주됩니다(평균 재임 6.4 년).

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/07/13 09:22
종가	2026/07/10 00:00
수익	2026/03/31
연간 수익	2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

MediciNova, Inc.는 7명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Lander Egaña-Gorroño	H.C. Wainwright & Co.
Elemer Piros	Lucid Capital Markets
Jason McCarthy	Maxim Group

MediciNova 경영진

경영진 기준 점검 2/4

핵심 정보

최근 경영진 업데이트

MediciNova, Inc., Annual General Meeting, Jun 23, 2026

MediciNova, Inc., Annual General Meeting, Jun 17, 2025

MediciNova, Inc., Annual General Meeting, Jun 11, 2024

Less than half of directors are independent

Chief Medical Officer & Director exercised options to buy US$229k worth of stock.

Co-Founder exercised options to buy US$492k worth of stock.

Recent updates

MediciNova Completes Phase 2 Milestone and Gains Key Patent Allowance

MediciNova Receives Notice Of Allowance For New Patent Covering Use Of MN-166 In Combination With Anti-PD-1 Immune Checkpoint Inhibitor For Glioblastoma Treatment

Forecast to breakeven in 2028

Consensus revenue estimates increase by 255%

Price target increased by 8.0% to US$9.00

MediciNova, Inc., Annual General Meeting, Jun 23, 2026

MediciNova, Inc. Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access- Program (EAP) Evaluating MN-166 (ibudilast) in ALS Patients

MediciNova, Inc. to Report Fiscal Year 2025 Results on Feb 13, 2026

MediciNova, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

MediciNova, Inc. Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-Induced Peripheral Neuropathy

MediciNova, Inc. Announces Update and Basic Characteristic Randomized Patients' of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS) in ALS (ALS) Presented at the 36th International Symposium on ALS/MND

MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

MediciNova, Inc. to Report Q3, 2025 Results on Nov 13, 2025

MediciNova, Inc. Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast)

MediciNova, Inc. Achieves Enrollment in COMBAT-ALS Clinical Trial

MediciNova, Inc. announced that it expects to receive $30 million in funding from Yorkville Advisors Global LP

MediciNova, Inc. Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials

MediciNova, Inc. to Report Q2, 2025 Results on Aug 14, 2025

MediciNova, Inc. to Report Q1, 2025 Results on May 14, 2025

MediciNova, Inc., Annual General Meeting, Jun 17, 2025

MediciNova, Inc. Announces First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients

MediciNova, Inc. to Report Fiscal Year 2024 Results on Feb 14, 2025

Medicinova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver

MediciNova, Inc. to Report Q3, 2024 Results on Nov 14, 2024

MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)

MediciNova, Inc. Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition

Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth

MediciNova, Inc. to Report Q2, 2024 Results on Aug 09, 2024

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer

MediciNova, Inc. Announces Data from Phase 1B/2A Clinical Trial of Mn-166 (Ibudilast) in Glioblastoma Patients At the American Society of Clinical Oncology (Asco) Annual Meeting 2024

MediciNova, Inc. Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome

MediciNova, Inc. Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)

MediciNova, Inc., Annual General Meeting, Jun 11, 2024

We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

MediciNova, Inc. to Report Q1, 2024 Results on May 10, 2024

MediciNova, Inc. Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan

Medicinova Announces New Data and Results of Mn-166 (Ibudilast) in Chlorine Gas-Induced Acute Lung Injury Presented At the 63Rd Annual Meeting of the Society of Toxicology

Price target increased by 69% to US$27.00

MediciNova, Inc. to Report Fiscal Year 2023 Results on Feb 14, 2024

MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China

MediciNova, Inc. Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-Induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology

MediciNova, Inc. Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe

MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans

MediciNova, Inc. Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada

MediciNova, Inc. to Report Q3, 2023 Results on Nov 10, 2023

Price target decreased by 41% to US$16.00

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology

MediciNova, Inc. Receives A Notice of Intention to Grant for A New Patent Covering MN-166 (Ibudilast) for the Treatment of Macular Injury in Europe

Less than half of directors are independent

We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

MediciNova, Inc. Announces Presentation of Results from the Phase 2B Trial of Mn-166 (Ibudilast) in Alcohol Use Disorder at the 46th Annual Research Society on Alcohol Use Disorder at the 46th Annual Research Society on Alcohol (RSA) Scientific Meeting

Here's Why We're Not Too Worried About MediciNova's (NASDAQ:MNOV) Cash Burn Situation

MediciNova Announces Health Canada Grants Authorization to Commence Multi-Arm Phase 2/3 Clinical Trial to Evaluate MN-166 (ibudilast) in Long COVID

MediciNova, Inc. Announces Completion of Enrollment in the Phase 2b Clinical Trial of MN 166 (ibudilast) in Alcohol Use Disorder

MediciNova, Inc. Announces Completion of Enrollment in the Phase 2 Clinical Trial Evaluating MN-166 (ibudilast) for Treatment of Recurrent and Newly Diagnosed Glioblastoma

MediciNova Receives Notice of Allowance for A New Patent Covering Mn-001 and Mn-002 for the Treatment of Scleroderma and Systemic Sclerosis in Canada

MediciNova, Inc. Receives Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Brazil

MediciNova, Inc. Completes Phase I Clinical Trial to Evaluate MN-166 10 MG Intravenous Infusion in Healthy Volunteers

Price target decreased to US$13.00

We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth

MediciNova to get US patent for MN-166 to treat brain cancer

MediciNova's MN-166 to be part of study to treat Long COVID

First half 2022 earnings released

MediciNova begins study of parenteral formulation of MN-166

MediciNova announces extension of BARDA contract for Ibudilast development

Price target decreased to US$13.00

We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

MediciNova (NASDAQ:MNOV) Is In A Strong Position To Grow Its Business

MediciNova: The Pain Of A Positive Outlook